ATHEROGENICS, INC.
Table of Contents

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549


FORM 8-K


CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): February 11, 2004

ATHEROGENICS, INC.
(Exact Name of Registrant as Specified in its Charter)

         
Georgia   0-31261   58-2108232
(State or other jurisdiction   (Commission   (I.R.S. Employer
of incorporation)   File Number)   Identification Number)

8995 Westside Parkway
Alpharetta, GA 30004

(Address of principal executive offices)

Registrant’s telephone number, including area code (678) 336-2500


 


TABLE OF CONTENTS

SIGNATURES
EXHIBIT INDEX
EX-99.1 PRESS RELEASE DATED FEBRUARY 11, 2004


Table of Contents

Item 7. Financial Statements, Pro Forma Financial Information and Exhibits

     Exhibits.

     The following exhibit is furnished as part of this current report on Form 8-K.

         
Exhibit No.       Description

     
99.1     Press Release dated February 11, 2004

Item 12. Results of Operations and Financial Condition.

     On February 11, 2004, AtheroGenics, Inc. issued a press release to report the company’s financial results for the quarter and year ended December 31, 2003. A copy of the press release is attached to this current report on Form 8-K as Exhibit 99.1.


2


Table of Contents

SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

     
    ATHEROGENICS, INC
     
Date: February 11, 2004   /s/ MARK P. COLONNESE
   
    Mark P. Colonnese
    Senior Vice President of Finance and
    Administration and Chief Financial Officer

3


Table of Contents

EXHIBIT INDEX

         
Exhibit No.       Description

     
99.1     Press Release dated February 11, 2004

4